MARKET

KTRA

KTRA

Kintara Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3945
-0.0034
-0.85%
Closed 17:44 01/26 EST
OPEN
0.3917
PREV CLOSE
0.3979
HIGH
0.4300
LOW
0.3833
VOLUME
433.22K
TURNOVER
--
52 WEEK HIGH
3.350
52 WEEK LOW
0.3330
MARKET CAP
19.15M
P/E (TTM)
-0.4390
1D
5D
1M
3M
1Y
5Y
20 Stocks Moving in Tuesday's Pre-Market Session
Gainers
Benzinga · 1d ago
53 Biggest Movers From Friday
Gainers Blue Star Foods Corp. (NASDAQ: BSFC) shares climbed 100% to close at $3.80 on Friday after gaining around 9% on Thursday.
Benzinga · 2d ago
34 Stocks Moving In Friday's Mid-Day Session
Gainers Blue Star Foods Corp. (NASDAQ: BSFC) shares jumped 180% to $5.32 after gaining around 9% on Thursday.
Benzinga · 5d ago
Kintara price target halved at H.C. Wainwright on extension to topline data read
Kintara Therapeutics (KTRA -4.2%) traded lower for the third straight session after H.C. Wainwright slashed its price target by 50%, noting that the company has pushed back its timeline for
Seekingalpha · 6d ago
10 Biggest Price Target Changes For Thursday
Piper Sandler cut Advanced Micro Devices, Inc. (NASDAQ: AMD) price target from $140 to $130. AMD shares fell 1.3% to $126.55 in pre-market trading.
Benzinga · 6d ago
--HC Wainwright Adjusts Kintara Therapeutics' Price Target to $3 From $6, Keeps Buy Rating
MT Newswires · 01/20 08:01
Kintara Announces Grant From Luxembourg National Research Fund And Cancer Foundation Luxembourg To Support VAL-083's Mechanism Of Action Research In Glioblastoma
SAN DIEGO, Jan. 12, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid
Benzinga · 01/12 13:02
Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2022 Virtual Conference
Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its Chief Executive Officer, Robert E. Hoffman will present at the H.C. Wainwright Bioconnect 2022 V...
PR Newswire · 01/05 13:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KTRA. Analyze the recent business situations of Kintara Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average KTRA stock price target is 4.200 with a high estimate of 5.00 and a low estimate of 3.000.
High5.00
Average4.200
Low3.000
Current 0.3945
EPS
Actual
Estimate
-0.18-0.14-0.09-0.05
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 37
Institutional Holdings: 5.35M
% Owned: 11.03%
Shares Outstanding: 48.54M
TypeInstitutionsShares
Increased
5
166.16K
New
12
2.60M
Decreased
8
61.04K
Sold Out
7
108.71K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.73%
Pharmaceuticals & Medical Research
-0.45%
Key Executives
President/Chief Executive Officer/Non-Executive Director/Independent Director
Robert Hoffman
Chief Financial Officer
Scott Praill
Senior Vice President
John Liatos
Chief Scientific Officer
Dennis Brown
Vice President - Research & Development
Steven Rychnovsky
Independent Director
Laura Johnson
Independent Director
Keith Murphy
Independent Director
Tamara Seymour
Independent Director
Robert Toth
No Data
About KTRA
Kintara Therapeutics, Inc. is a clinical-stage, biopharmaceutical company focused on the development and commercialization of new cancer therapies. The Company is developing two late-stage, Phase III-ready therapeutics. The Company's two lead product candidates are VAL-083 and REM-001. VAL- 083 is a validated, Deoxyribonucleic acid (DNA)-targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC) and diffuse intrinsic pontine glioma (DIPG). REM-001 is a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC). The Company is carrying out various clinical trials on brain tumor and solid tumor.

Webull offers kinds of Kintara Therapeutics Inc stock information, including NASDAQ:KTRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KTRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KTRA stock methods without spending real money on the virtual paper trading platform.